EDBT 2026 Demo / reviewers in the wild / expert
Jacob D. Galson
dblp:325/3827
· DBLP profile ↗
1ranked-venue papers
0as first author
1since 2021 · last 2022
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 5 heaviest of 5, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › protein design
antibody engineering |
0.6 | 1 | 2022 | AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design · Bioinform. 2022 |
Bioinformatics and computational biology › immunoinformatics
b cell repertoire analysis |
0.6 | 1 | 2022 | AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design · Bioinform. 2022 |
Bioinformatics and computational biology
immunoinformatics |
0.6 | 1 | 2022 | AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design · Bioinform. 2022 |
Bioinformatics and computational biology › protein design
therapeutic antibody design |
0.6 | 1 | 2022 | AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design · Bioinform. 2022 |
Bioinformatics and computational biology › genomics
next-generation sequencing data analysis |
0.2 | 1 | 2022 | AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design · Bioinform. 2022 |
Methods — techniques the papers use, named apart from their topics
sequence database search · 0.6positional variability statistics · 0.6
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2022 | AbDiver: a tool to explore the natural antibody landscape to aid therapeutic designabstractMOTIVATION: Rational design of therapeutic antibodies can be improved by harnessing the natural sequence diversity of these molecules. Our understanding of the diversity of antibodies has recently been greatly facilitated through the deposition of hundreds of millions of human antibody sequences in next-generation sequencing (NGS) repositories. Contrasting a query therapeutic antibody sequence to naturally observed diversity in similar antibody sequences from NGS can provide a mutational roadmap for antibody engineers designing biotherapeutics. Because of the sheer scale of the antibody NGS datasets, performing queries across them is computationally challenging. RESULTS: To facilitate harnessing antibody NGS data, we developed AbDiver (http://naturalantibody.com/abdiver), a free portal allowing users to compare their query sequences to those observed in the natural repertoires. AbDiver offers three antibody-specific use-cases: (i) compare a query antibody to positional variability statistics precomputed from multiple independent studies, (ii) retrieve close full variable sequence matches to a query antibody and (iii) retrieve CDR3 or clonotype matches to a query antibody. We applied our system to a set of 742 therapeutic antibodies, demonstrating that for each use-case our system can retrieve relevant results for most sequences. AbDiver facilitates the navigation of vast antibody mutation space for the purpose of rational therapeutic antibody design. AVAILABILITY AND IMPLEMENTATION: AbDiver is freely accessible at http://naturalantibody.com/abdiver. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Jakub Mlokosiewicz, Piotr Deszynski, Wiktoria Wilman, Igor Jaszczyszyn, Rajkumar Ganesan, Aleksandr Kovaltsuk, Jinwoo Leem, Jacob D. Galson, Konrad Krawczyk |
Bioinform. | 8 |